Breast Cancer, Implant Breast Reconstruction, Neoadjuvant Radiotherapy
Conditions
Keywords
neoadjuvant radiotherapy, implant, breast reconstruction
Brief summary
Neoadjuvant radiotherapy(NART) followed by mastectomy and immediate DIEP flap reconstruction is feasible and technically safe. However, reports of NACT followed immediate implant-based breast reconstruction are rare. Some studies have shown that NART followed immediate implant-based breast reconstruction seems feasible and can be safely attempted. It's well known that radiotherapy after implant-based breast reconstruction have negative effects on implant and cosmetic results. So, investigators conducted a polit study to learn about acute post-surgical complications following skin-sparing mastectomy and immediate implant-based breast reconstruction after NART.
Detailed description
Radiotherapy after implant-based breast reconstruction have negative effects on implant and cosmetic results, including severe capsular contracture, mastectomy flap necrosis ,reoperation and so on. Postmastectomy radiotherapy( PMRT )is associated with implant reconstruction failure. PRADA study has shown neoadjuvant radiotherapy followed by skin-sparing mastectomy and immediate DIEP flap reconstruction is feasible and technically safe. The investigators assume that neoadjuvant radiotherapy can avoid the negative effects of PMRT on an implant and the capsule of an implant and would lead to better cosmetic results and less complications compared to PMRT. Furthermore, some studies have shown that NART could potentially result in shorter time between diagnosis and treatment completion. So, investigators conducted a polit study to learn about acute post-surgical complications following skin-sparing mastectomy and immediate implant-based breast reconstruction after NART.
Interventions
RADIATIONNeoadjuvant radiotherapy
In case of neoadjuvant chemotherapy, RT will start 3-4 weeks after the last course of chemotherapy. A dose of 15 x 2.67 Gy 5 fractions or 16 x 2.67Gy 5 fractions per week. A skin-sparing mastectomy and a immediate implant-based breast reconstruction will be performed, approximately 2-6 weeks after latest radiotherapy treatment.
Sponsors
Hubei Cancer Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
Women \>18 years with histopathologically-confirmed breast cancer, who: * require mastectomy for any reason * a known indication for (adjuvant) radiotherapy * require implant-based breast reconstruction
Exclusion criteria
* Inability to give informed consent * MDT unable to make recommendation for radiotherapy based on pre-operative histopathological and imaging findings * Previous history of breast cancer or another malignancy for which radiotherapy of the breast or axilla * Pregnant or lactating * inflammatory breast cancer
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Postoperative complications at 3 months following skin-sparing mastectomy and immediate implant-based breast reconstruction after NART | 3 months following skin-sparing mastectomy and immediate breast reconstruction | Surgical complications are defined as any complication requiring surgical intervention necessary within a period up to three months after the final reconstruction. Including Infection, hematoma , loss of implant or flap, fat necrosis, wound breakdown,defined and scored using the C-DC37. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 . | Within 3 months after both breast reconstruction and radiotherapy | Other adverse events following NART or surgery other than described in the primary outcome measure. |
| Number of participants with removal of implant. | 6 months after surgery | Implant are removed for postoperative complications. |
| Patient satisfaction. | 3 months and 12 months after surgery | Patient satisfaction (as measured using the BREAST-Q reconstruction module) before, 3 months after, and 12 months after surgery. |
| Pathological complete response (pCR) assessed in skin-sparing mastectomy specimen | Within 2 weeks after skin-sparing mastectomy | A pCR was defined as absence of invasive and in situ carcinoma in the breast, irrespective of nodal status (ypT0). |
Countries
China
Contacts
Primary ContactXinhong Wu, MD
Backup ContactNing Zou, MD
Outcome results
None listed